TP53 Loss of Heterozygosity Induces De Novo SCLC Formation in EGFR-Mutated Lung Adenocarcinoma: A Case Report.
JTO Clin Res Rep
; 3(5): 100305, 2022 May.
Article
in En
| MEDLINE
| ID: mdl-35498386
ABSTRACT
SCLC transformation in EGFR-mutated lung adenocarcinoma is one of the major phenotypic changes that is observed during the resistance to EGFR tyrosine kinase inhibitors. However, the mechanism of this transformation remains unclear. In this study, we found a small de novo SCLC component in surgically resected specimens of EGFR-mutated lung adenocarcinoma before EGFR tyrosine kinase inhibitor treatment. By using laser microdissection and whole-exome sequencing, TP53 loss of heterozygosity was found to be possibly involved in SCLC transformation.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
JTO Clin Res Rep
Year:
2022
Document type:
Article
Affiliation country:
Japón